MADISON, Wis.–EraGen Biosciences Inc., a developer of novel molecular reagents for the in-vitro diagnostics (IVD) market, and Illumina Inc., a global company that develops, manufactures and markets integrated systems for analysis of genetic variation and biological function, today announced the formation of a strategic partnership and the execution of non-exclusive licensing agreements.

Under these licensing agreements, EraGen Biosciences will have access to Illumina’s BeadXpress platform for the continued development and commercialization of molecular-based, high-throughput clinical multiplexed assays with its unique, patented MultiCode®-PLx technology. EraGen has proven commercial success with multiplex molecular assays for the infectious disease and genetic disorder markets. Illumina has licensed EraGen’s MultiCode-PLx technology for the life sciences, research and clinical markets.

“We are very excited by the opportunities this partnership presents to EraGen. Our newly formed relationship with Illumina further validates our MultiCode technology’s versatile application in the development and commercialization of molecular-based assays for the clinical market,” stated Irene Hrusovsky, M.D., President and CEO of EraGen Biosciences Inc.

“We look forward to seeing the delivery of innovative solutions through the combination of Illumina and EraGen technologies,” said Greg Heath, Senior Vice President and GM of Illumina’s diagnostic division. “We view this agreement as a first step toward advancing healthcare through leading-edge molecular tools.”

This partnership is part of EraGen’s strategy to continue to expand its commercial efforts in the molecular diagnostics market.

“We will continue to bring to market innovative, high-value molecular diagnostic tests and solutions through strategic platform partnerships and the advancement of a broad product pipeline that is responsive to our customers’ needs,” added Dr. Hrusovsky.

EraGen’s goal is to provide its customers in the molecular diagnostics laboratory with an integrated solution that provides rapid, reliable results for improving the clinical management of patients.

About EraGen Biosciences

EraGen Biosciences develops, manufactures and markets molecular reagent products that are driving a new era in clinical diagnostics. The company’s in-market and pipeline products, based on its novel, patented MultiCode® platform chemistry, are the next generation of DNA- and RNA-based testing for the early detection of infectious diseases and genetic-based conditions. EraGen’s expanding menu of high quality, easy-to-use products position the company for leadership in the molecular diagnostics market. For more information, visit the EraGen website at www.eragen.com.